A citation-based method for searching scientific literature

Thomas Danne, Steven Edelman, Juan Pablo Frias, Francisco Javier Ampudia-Blasco, Philip Banks, Wenjun Jiang, Michael J Davies, Sangeeta Sawhney. Diabetes Obes Metab 2021
Times Cited: 3







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trends over 8 years in quality of diabetes care: results of the AMD Annals continuous quality improvement initiative.
Maria Chiara Rossi, Riccardo Candido, Antonio Ceriello, Antonino Cimino, Paolo Di Bartolo, Carlo Giorda, Katherine Esposito, Giuseppe Lucisano, Marina Maggini, Edoardo Mannucci,[...]. Acta Diabetol 2015
23
33


Insulin therapy, weight gain and prognosis.
Israel Hodish. Diabetes Obes Metab 2018
9
33

Identification of barriers to insulin therapy and approaches to overcoming them.
David Russell-Jones, Frans Pouwer, Kamlesh Khunti. Diabetes Obes Metab 2018
88
33

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
R H A Becker, I Nowotny, L Teichert, K Bergmann, C Kapitza. Diabetes Obes Metab 2015
75
33



New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Philip D Home, Richard M Bergenstal, Geremia B Bolli, Monika Ziemen, Maria Rojeski, Melanie Espinasse, Matthew C Riddle. Diabetes Care 2015
113
33

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Tim Heise, Ulrike Hövelmann, Leszek Nosek, Lidia Hermanski, Susanne G Bøttcher, Hanne Haahr. Expert Opin Drug Metab Toxicol 2015
74
33


Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
Fang Liz Zhou, Fen Ye, Paulos Berhanu, Vineet E Gupta, Rishab A Gupta, Jennifer Sung, Jukka Westerbacka, Timothy S Bailey, Lawrence Blonde. Diabetes Obes Metab 2018
44
33

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, John Cooper, Edward Franek, David Russell-Jones, Jens Larsen, Søren Can Tamer, Stephen C Bain. J Clin Endocrinol Metab 2013
145
33

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
233
33


Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety.
Paola Ponzani, Cesare Berra, Alessandra Di Lelio, Paola Del Sindaco, Chiara Di Loreto, Francesco Reggiani, Giuseppe Lucisano, Maria Chiara Rossi. Diabetes Ther 2020
4
33

New forms of insulin and insulin therapies for the treatment of type 2 diabetes.
Avivit Cahn, Roberto Miccoli, Angela Dardano, Stefano Del Prato. Lancet Diabetes Endocrinol 2015
49
33


More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Julio Rosenstock, Alice Cheng, Robert Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M G Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P Frías,[...]. Diabetes Care 2018
97
33



Gender-Disparities in Adults with Type 1 Diabetes: More Than a Quality of Care Issue. A Cross-Sectional Observational Study from the AMD Annals Initiative.
Valeria Manicardi, Giuseppina Russo, Angela Napoli, Elisabetta Torlone, Patrizia Li Volsi, Carlo Bruno Giorda, Nicoletta Musacchio, Antonio Nicolucci, Concetta Suraci, Giuseppe Lucisano,[...]. PLoS One 2016
14
33

A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes.
Thorsten Siegmund, Nikolaos Tentolouris, Søren T Knudsen, Annunziata Lapolla, Rudolf Prager, Tra-Mi Phan, Michael L Wolden, Bernd Schultes. Diabetes Obes Metab 2018
26
33

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
224
33

Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections.
Richard M Bergenstal, Timothy S Bailey, David Rodbard, Monika Ziemen, Hailing Guo, Isabel Muehlen-Bartmer, Andrew J Ahmann. Diabetes Care 2017
68
33

Hypoglycemia in diabetes.
Philip E Cryer, Stephen N Davis, Harry Shamoon. Diabetes Care 2003
741
33

Symptomatic hypoglycaemia in 411 type 1 diabetic patients.
S Pramming, B Thorsteinsson, I Bendtson, C Binder. Diabet Med 1991
263
33


Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Simon Heller, John Buse, Miles Fisher, Satish Garg, Michel Marre, Ludwig Merker, Eric Renard, David Russell-Jones, Areti Philotheou, Ann Marie Ocampo Francisco,[...]. Lancet 2012
236
33

The importance of the initial period of basal insulin titration in people with diabetes.
Kamlesh Khunti, Francesco Giorgino, Lori Berard, Didac Mauricio, Stewart B Harris. Diabetes Obes Metab 2020
8
33

Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
Marc L Berger, Harold Sox, Richard J Willke, Diana L Brixner, Hans-Georg Eichler, Wim Goettsch, David Madigan, Amr Makady, Sebastian Schneeweiss, Rosanna Tarricone,[...]. Value Health 2017
95
33



Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials.
Thomas Danne, Munehide Matsuhisa, Christian Sussebach, Harmonie Goyeau, Felipe Lauand, Elisabeth Niemoeller, Geremia B Bolli. Diabetes Obes Metab 2020
8
33

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Hannele Yki-Järvinen, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle, Matthew C Riddle. Diabetes Care 2014
178
33

ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome.
Dario Cattaneo, Piero Ruggenenti, Sara Baldelli, Nicola Motterlini, Eliana Gotti, Silvio Sandrini, Maurizio Salvadori, Giuseppe Segoloni, Paolo Rigotti, Donato Donati,[...]. J Am Soc Nephrol 2009
50
33

Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials.
Claudia Sommerer, Oliver Witzke, Frank Lehner, Wolfgang Arns, Petra Reinke, Ute Eisenberger, Bruno Vogt, Katharina Heller, Johannes Jacobi, Markus Guba,[...]. BMC Nephrol 2018
9
33

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.
Valeriya Lyssenko, Roberto Lupi, Piero Marchetti, Silvia Del Guerra, Marju Orho-Melander, Peter Almgren, Marketa Sjögren, Charlotte Ling, Karl-Fredrik Eriksson, Asa-Linda Lethagen,[...]. J Clin Invest 2007
520
33


Metformin use in kidney transplant recipients in the United States: an observational study.
Jenise Stephen, Teresa L Anderson-Haag, Sally Gustafson, Jon J Snyder, Bertram L Kasiske, Ajay K Israni. Am J Nephrol 2014
27
33


Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal.
Karsten Midtvedt, Jøran Hjelmesaeth, Anders Hartmann, Kirsten Lund, Dag Paulsen, Thore Egeland, Trond Jenssen. J Am Soc Nephrol 2004
116
33



Genetics of new-onset diabetes after transplantation.
Jennifer A McCaughan, Amy Jayne McKnight, Alexander P Maxwell. J Am Soc Nephrol 2014
50
33

Gender issues in transplantation.
Marie Csete. Anesth Analg 2008
36
33

Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients.
Florian Kälble, Jörg Seckinger, Matthias Schaier, Christian Morath, Vedat Schwenger, Martin Zeier, Claudia Sommerer. Clin Transplant 2017
10
33

Prognostic Value of Proinflammatory Markers in Patients After Kidney Transplantation in Relation to the Presence of Diabetes.
D Cieniawski, P Miarka, E Ignacak, A Bętkowska-Prokop, M Waluś-Miarka, B Idzior-Waluś, M Kuźniewski, W Sułowicz. Transplant Proc 2016
4
33

Renal transplantation in elderly patients older than 70 years of age: results from the Scientific Registry of Transplant Recipients.
Panduranga S Rao, Robert M Merion, Valarie B Ashby, Friedrich K Port, Robert A Wolfe, Liise K Kayler. Transplantation 2007
275
33

Significant associations between CCL5 gene polymorphisms and post-transplantational diabetes mellitus in Korean renal allograft recipients.
Kyung-Hwan Jeong, Joo-Young Moon, Joo-Ho Chung, Young-Hoon Kim, Tae-Won Lee. Am J Nephrol 2010
16
33

Immunosuppressive drug-induced diabetes.
A Penfornis, S Kury-Paulin. Diabetes Metab 2006
81
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.